Invivyd’s PEMGARDA Revenue Rises 18% to $15.4 Million in Third Quarter
Key Facts
Invivyd reported net revenue of $15.4 million from PEMGARDA in the quarter ended September 30, 2026, up 18% from the same period in 2025, driven mainly by increased patient demand, according to the company’s earnings statement. At the same time, its net loss widened to $33.5 million, compared with $10.5 million a year earlier. Basic and diluted loss per share was $0.10, versus $0.06 in the third quarter of 2025. The results reflect growth in product sales alongside higher expenses and lower profitability. The financial challenge centers on the company’s ability to continue funding its operations, while its current revenue depends on a product facing a defined regulatory deadline.
Third-quarter revenue was higher than the $14.3 million the company reported in the second quarter of 2026, when revenue was $11.8 million in the same period of 2025. This shows revenue continued to grow from year-earlier levels in both the second and third quarters. The company attributed the year-over-year increase in the third quarter mainly to higher patient demand for PEMGARDA. But sales growth did not keep pace with the increase in spending: research and development expenses rose to $18.7 million from $8.0 million in the third quarter of 2025. The company said the increase was mainly due to contract research costs for the DECLARATION and LIBERTY trials of candidate VYD2311.
Selling, general and administrative expenses also rose to $30.3 million in the third quarter, compared with $15.0 million a year earlier. Invivyd attributed the increase to employee costs, communications and commercial activities. The rise in these expenses coincided with higher spending on clinical trials, weighing on results despite increased product revenue. The company’s net loss for the nine months ended September 30, 2026, was $119.261 million, compared with $41.419 million in the corresponding period of 2025. This puts the nine-month losses in the broader context of a widening quarterly loss.
Cash and cash equivalents totaled $126.4 million on September 30, 2026, down from $160.1 million on June 30, 2026. In its quarterly report, the company said that, based on its current operating plans and without future external financing, it does not expect to have enough liquidity to cover operating expenses and capital requirements beyond one year from the date the financial statements are issued. It concluded that substantial doubt exists about its ability to continue as a going concern. The warning puts liquidity at the center of the company’s financial outlook, as increased spending on clinical and commercial programs coincides with higher losses. The filing did not identify future external financing that could be included in these estimates.
On clinical development, the company plans to conduct a prespecified interim analysis in the Phase 3 DECLARATION trial, evaluating serum neutralizing antibody titers, pharmacokinetics, immunogenicity and safety for candidate VYD2311. The company will keep the clinical disease events collected so far blinded in the analysis design. Chief Executive Mark Iulia said, "We look forward to presenting DECLARATION data and providing a regulatory update soon." The company had said the trial was targeting about 2,400 participants, while the total target enrollment in the LIBERTY trial was about 210 participants. This follow-up comes after Invivyd announced positive initial results from LIBERTY in September, saying VYD2311 met its primary and secondary endpoints and showed superior safety and tolerability compared with an mRNA-based COVID vaccine.
PEMGARDA’s sales outlook is also tied to the end of the product’s emergency use authorization on June 29, 2027. The company said the termination follows a 12-month transition period that began with advance notice on June 30, 2026, and that it is in discussions with the U.S. Food and Drug Administration about next steps. According to its quarterly report, it will not be able to sell the product after the authorization ends unless it obtains regulatory approval. Invivyd plans to hold an event for investors in the medical and commercial fields during the first half of 2027 to present its commercial plans and early indicators of institutional demand for VYD2311. DECLARATION data and the anticipated regulatory update remain the key near-term milestones, amid a defined regulatory timeline for a product that generated $15.4 million in revenue in the third quarter.